Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Paion AG's share price for the quarter that ended in Jun. 2023 was $0.94. Paion AG's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 7.13 Mil. Therefore, Paion AG's market cap for the quarter that ended in Jun. 2023 was $6.71 Mil.
Paion AG's quarterly market cap
declined
from Jun. 2022 ($89.18 Mil) to Dec. 2022 ($28.54 Mil) and
declined
from Dec. 2022 ($28.54 Mil) to Jun. 2023 ($6.71 Mil).
Paion AG's annual market cap
declined
from Dec. 2020 ($194.23 Mil) to Dec. 2021 ($99.88 Mil) and
declined
from Dec. 2021 ($99.88 Mil) to Dec. 2022 ($28.54 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Paion AG's Enterprise Value for Today is $0.11 Mil.
Paion AG (OTCPK:PAIOF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Paion AG Market Cap Related Terms
Paion AG Market Cap Historical Data
* Premium members only.
The historical data trend for Paion AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paion AG Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Paion AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Paion AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Paion AG's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paion AG (PAIOF) has a Market Cap of $0.11 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Paion AG and its competitors.
Is Paion AG's Market Cap too high?
Paion AG's current Market Cap is $0.11 Mil. The Drug Manufacturers industry median Market Cap is 206.50. Paion AG's value of $0.11 Mil is 99.9% below this industry median. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Market Cap compare to ZTS and NBIX?
Paion AG's Market Cap of $0.11 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 206.50. Paion AG's value of $0.11 Mil is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.50, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paion AG's current Market Cap of $0.11 Mil is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current Market Cap is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Market Cap of $0.11 Mil. The current Market Cap is $0.11 Mil and 99.9% below the Drug Manufacturers industry median of 206.50. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Paion AG (PAIOF), the current Market Cap is $0.11 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score
Get the complete analysis for PAIOF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAIOF has been successfully added to your 
